Study Finds U-Shaped Link Between TyG-BMI and Mortality Risks in Osteoarthritis Patients, Highlighting IR Role

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-10-13 14:30 GMT   |   Update On 2024-10-13 14:30 GMT
Advertisement

China: A recent analysis of National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2020 has unveiled a U-shaped nonlinear relationship between the triglyceride glucose-body mass index (TyG-BMI) and both all-cause and cardiovascular mortality among adults with osteoarthritis (OA) in the United States.

The findings, published in Scientific Reports, highlight the complex role that insulin resistance (IR) plays in the health outcomes of these patients.

Advertisement

"Mortality risks escalated when TyG-BMI levels exceeded thresholds of 282 for all-cause mortality and 270 for cardiovascular mortality. For each 10-unit increase above these thresholds, there was a corresponding 3% rise in the risk of all-cause mortality and a 5% increase in cardiovascular mortality risk," the researchers reported.

The TyG-BMI index, a composite measure combining triglyceride levels, glucose levels, and body mass index, has been increasingly recognized for its potential in assessing metabolic health and the risk of adverse outcomes. The relationship between insulin resistance and all-cause and cardiovascular mortality risk in osteoarthritis patients is still unclear. Considering this, Wenbo Ding, China Medical University, Liaoning, People’s Republic of China, and colleagues aimed to clarify the correlation between a novel marker of IR, the TyG-BMI index, and the risk of all-cause mortality and cardiovascular mortality in OA patients.

For this purpose, the researchers analyzed data from the NHANES covering 1999 to 2020. They used multivariable Cox proportional hazards regression analysis and restricted cubic spline plots to investigate the relationship between the TyG-BMI index and all-cause and cardiovascular mortality risk among osteoarthritis patients. To further refine their findings, subgroup analyses were performed to examine potential interactions and identify populations at higher mortality risk.

The study included a cohort of 4,097 OA patients who were followed for 20 years, during which 1,197 cases of all-cause mortality and 329 cases of cardiovascular mortality were documented.

The following were the key findings of the study:

  • There was a U-shaped nonlinear relationship between the TyG-BMI index and the risk of all-cause mortality or cardiovascular mortality in OA patients, with the lowest mortality risk thresholds identified at 282 and 270, respectively.
  • Surpassing these thresholds was associated with a 3% increase in the risk of all-cause mortality and a 5% increase in the risk of cardiovascular mortality for every 10-unit increment in TyG-BMI level.

The study reveals a U-shaped nonlinear relationship between TyG-BMI levels and all-cause and cardiovascular mortality in osteoarthritis (OA) patients, identifying a specific TyG-BMI index threshold associated with the lowest mortality risk. This finding offers clinicians a new perspective and potential intervention target for identifying and addressing OA patients at higher mortality risk.

"The research highlights the value of the TyG-BMI index in assessing insulin resistance (IR) to predict OA patient outcomes and suggests that insulin therapy could benefit these patients," the researchers concluded.

Reference:

Wang, W., Zhou, F., Li, Y., Liu, Y., Sun, H., Lv, Q., & Ding, W. (2024). U-shaped association between triglyceride glucose-body mass index with all-cause and cardiovascular mortality in US adults with osteoarthritis: Evidence from NHANES 1999–2020. Scientific Reports, 14(1), 1-10. https://doi.org/10.1038/s41598-024-70443-1


Tags:    
Article Source : Scientific Reports

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News